Guardant Health Introduces GuardantINFINITY™ Smart Liquid Biopsy for Research Use to Help Bring New Cancer Therapies to Patients Sooner

• Next-generation assay combines 800+-gene panel with exome-wide methylation detection to provide novel genomic and epigenomic insights into tumor, tumor microenvironment and patient immune responses from a simple blood draw
• Researchers can access additional modular content to gain insight into and direct patient selection for IO, HRD and other targeted therapies with no need for additional sample collection

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today the introduction of GuardantINFINITY™, a next-generation liquid biopsy that provides new, multi-dimensional insights into the complexities of tumor molecular profiles and immune response to advance cancer research and therapy development.

The new GuardantINFINITY assay provides a more comprehensive molecular profile of tumors than earlier assays, giving researchers access to novel genomic and epigenomic insights to provide a simultaneously deeper and more complete understanding of a tumor’s biology, its system-wide interactions and the associated immune response in a range of applications—from therapy selection to molecular response and longitudinal monitoring. The assay’s extensive methylome panel helps identify the unique, exome-wide methylation pattern that each tumor delivers, providing an important new dimension of research insights that has been largely unexplored in clinical development to date.

“Realizing the promise of precision medicine demands a comprehensive, multi-dimensional understanding of the tumor, the tumor microenvironment and the patient’s immune response,” said Helmy Eltoukhy, Guardant Health co-CEO. “GuardantINFINITY, the first product from our new smart liquid biopsy platform, represents a quantum leap forward in the capabilities of liquid biopsies to provide those insights. Drawing on 10 years of research and experience from hundreds of thousands of liquid biopsies, this new assay allows researchers to gain unprecedented insight into a tumor’s molecular underpinnings and its systemic complex interactions to help them accelerate the development of much-needed cancer therapies.”

The new platform will enable countless new liquid biopsy applications over time, from deep interrogation of the tumor microenvironment to diverse immuno-oncology applications, much more sensitive therapeutic monitoring, identification of complex prognostic signatures and innate resistance to certain therapies, and more.

GuardantINFINITY is available as a single modular assay with flexible configurations that can be tailored to fit a current application, along with the ability to unlock additional content modules at any time, without incurring the burden or delay of additional sample collection. The core module offers genotyping coverage of more than 800 genes with sample-level methylation detection and tumor fraction score for biomarker discovery, clinical research, therapy selection and response monitoring.

The GuardantINFINITY liquid biopsy is currently available for research use only.

About Guardant Health

Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has commercially launched Guardant360®, Guardant360 CDx, Guardant360 TissueNext™, Guardant360 Response™, and GuardantOMNI® tests for advanced stage cancer patients, and Guardant Reveal™ for early-stage cancer patients. The Guardant Health screening portfolio, including the Shield™ test, aims to address the needs of individuals eligible for cancer screening. For more information, visit guardanthealth.com and follow the company on LinkedIn and Twitter.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health’s liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2021 and in its other reports filed with the Securities and Exchange Commission. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health’s views as of any date subsequent to the date of this press release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220909005520/en/